Drug Trial Radar · NCT07441395
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Corvus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment
Conditions
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
- Eczema, Atopic
Interventions
SoquelitinibDrug
Soquelitinib tablets
PlaceboDrug
Soquelitinib matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12Time frame: Baseline through Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Corvus Clinical Trials
South San Francisco, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.